問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

Division of Dermatology

更新時間：2023-09-19

翁孟玉Weng, Meng-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

翁孟玉

National Taiwan University Hospital

Division of Rheumatology

List

10Cases

2021-10-01 - 2027-08-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting2Sites

Terminated1Sites

2022-12-14 - 2026-12-31

Phase III

Active
A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients

  • Condition/Disease

    Gout

  • Test Drug

    錠劑

Participate Sites
13Sites

Recruiting13Sites

2017-08-11 - 2020-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    CNTO1959(guselkumab)

Participate Sites
7Sites

Terminated7Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

2017-07-26 - 2022-06-30

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis

  • Condition/Disease

    Arthritis, Psoriatic

  • Test Drug

    CNTO1959(guselkumab)

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2015-09-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Refractory Subjects With Active Radiographic Axial Spondyloarthritis

  • Condition/Disease

    Active Radiographic Axial Spondyloarthritis

  • Test Drug

    STELARA

Participate Sites
10Sites

Terminated10Sites

2015-09-01 - 2020-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2015-09-01 - 2018-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

羅淑芬
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2012-08-01 - 2016-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-01-01 - 2020-06-30

Phase III

A Phase 3 Multicenter, Randomized, Double-blind,Placebo-controlled Study with an Open Label Extension to Evaluatethe Efficacy and Safety of KHK4827 in Subjects with Axial Spondyloarthritis

  • Condition/Disease

    Axial Spondyloarthritis

  • Test Drug

    KHK4827 (Brodalumab)

Participate Sites
13Sites

Terminated11Sites

羅淑芬
Linkou Chang Gung Medical Foundation

黃春明
China Medical University Hospital-Taipei

未分科

2014-03-14 - 2020-07-22

Phase IV

PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS

  • Condition/Disease

    rheumatoid arthritis

  • Test Drug

    Xeljanz

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB